{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:53:28Z","timestamp":1790834008855,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UL1TR000114"],"award-info":[{"award-number":["UL1TR000114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","amjmedsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.amjms.2016.12.013","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T22:50:11Z","timestamp":1481928611000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Characterization of Mast Cell Activation Syndrome"],"prefix":"10.1016","volume":"353","author":[{"given":"Lawrence B.","family":"Afrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Menk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lazarchick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2016.12.013_bib1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib2","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1182\/blood-2010-01-257287","article-title":"Mast cell proteases: multifaceted regulators of inflammatory disease","volume":"115","author":"Pejler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.trsl.2016.01.001","article-title":"Transgenerational transmission of systemic mast cell activation disease\u2014genetic and epigenetic features","volume":"174","author":"Molderings","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.amjms.2016.12.013_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jaci.2010.12.1113","article-title":"Toward a global classification of mast cell activation diseases","volume":"127","author":"Molderings","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2567.2012.03627.x","article-title":"Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics","volume":"137","author":"Haenisch","year":"2012","journal-title":"Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib6","doi-asserted-by":"crossref","first-page":"e76241","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2016.12.013_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MAJ.0b013e31821d41dd","article-title":"Polycythemia from mast cell activation syndrome: lessons learned","volume":"342","author":"Afrin","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2016.12.013_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7205\/MILMED-D-11-00111","article-title":"Mast cell activation syndrome masquerading as agranulocytosis","volume":"177","author":"Afrin","year":"2012","journal-title":"Mil Med"},{"key":"10.1016\/j.amjms.2016.12.013_bib9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.amjms.2016.12.013_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tripleo.2010.11.030","article-title":"Burning mouth syndrome and mast cell activation disorder","volume":"111","author":"Afrin","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiology Endod"},{"key":"10.1016\/j.amjms.2016.12.013_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri3690","article-title":"Mast cell secretory granules: armed for battle","volume":"14","author":"Wernersson","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib13","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.4049\/jimmunol.181.7.5024","article-title":"Secretogranin III directs secretory vesicle biogenesis in mast cells in a manner dependent upon interaction with chromogranin A","volume":"181","author":"Prasad","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib14","unstructured":"Ibelgaufts H. \u201cMast Cells\u201d in COPE: Cytokines and Cells Online Pathfinder Encyclopaedia, 2015. Available at: http:\/\/www.cells-talk.com\/index.php\/page\/copelibrary?key=mast%20cells. Accessed April 2, 2016."},{"key":"10.1016\/j.amjms.2016.12.013_bib15","first-page":"1","article-title":"On the role of PGD2 metabolites as markers of mast cell activation in asthma","volume":"644","author":"O\u05f3Sullivan","year":"1999","journal-title":"Acta Physiol Scand Suppl"},{"issue":"6","key":"10.1016\/j.amjms.2016.12.013_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/thx.2004.026641","article-title":"Monitoring mast cell activation by prostaglandin D2 in vivo","volume":"59","author":"Dahl\u00e9n","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.amjms.2016.12.013_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1160\/TH11-05-0351","article-title":"Bleeding diathesis in patients with mast cell activation disease","volume":"106","author":"Seidel","year":"2011","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.amjms.2016.12.013_bib18","doi-asserted-by":"crossref","first-page":"e0124912","DOI":"10.1371\/journal.pone.0124912","article-title":"Determination of plasma heparin level improves identification of systemic mast cell activation disease","volume":"10","author":"Vysniauskaite","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2016.12.013_bib19","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJM198312293092603","article-title":"Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites","volume":"309","author":"Keyzer","year":"1983","journal-title":"N Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.amjms.2016.12.013_bib20","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1111\/1523-1747.ep12468945","article-title":"Biochemical diagnosis of systemic mast cell disorders","volume":"96","author":"Roberts","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.amjms.2016.12.013_bib21","first-page":"469","article-title":"The measurement of leukotrienes in urine as diagnostic option in systemic mastocytosis","volume":"62","author":"Raithel","year":"2011","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.amjms.2016.12.013_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.amjms.2016.12.013_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.amjms.2016.12.013_bib24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0145-2126(01)00050-9","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis","volume":"25","author":"Escribano","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.amjms.2016.12.013_bib25","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1182\/blood.V122.21.5240.5240","article-title":"Characterization of common blood test abnormalities potentially aiding diagnosis of mast cell activation syndrome: a preliminary analysis","volume":"122","author":"Afrin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib26","series-title":"Hematology: Basic Principles and Practice","first-page":"303","article-title":"Granulocytopoiesis and monocytopoiesis","author":"Khanna-Gupta","year":"2008"},{"key":"10.1016\/j.amjms.2016.12.013_bib27","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V70.5.1700.1700","article-title":"Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes","volume":"70","author":"Oster","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-3083.1995.tb03628.x","article-title":"Constitutive and inducible cytokine mRNA expression in the human mast cell line HMC-1","volume":"42","author":"Nilsson","year":"1995","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejphar.2012.12.003","article-title":"Inhibitory effects of benzodiazepines on the adenosine A(2B) receptor mediated secretion of interleukin-8 in human mast cells","volume":"700","author":"Hoffmann","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.amjms.2016.12.013_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-11-13","article-title":"The 1,4-benzodiazepine Ro5-4864 (4-chlorodiazepam) suppresses multiple pro-inflammatory mast cell effector functions","volume":"11","author":"Yousefi","year":"2013","journal-title":"Cell Commun Signal"},{"issue":"20","key":"10.1016\/j.amjms.2016.12.013_bib31","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria, and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.amjms.2016.12.013_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5315\/wjh.v3.i1","article-title":"A concise, practical guide to diagnostic assessment for mast cell activation disease","volume":"3","author":"Afrin","year":"2014","journal-title":"World J Hematol"},{"key":"10.1016\/j.amjms.2016.12.013_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2016.12.013_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2016.01.003","article-title":"Mast cell activation disease and the modern epidemic of chronic inflammatory disease","volume":"174","author":"Afrin","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.amjms.2016.12.013_bib36","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1007\/s10620-014-3181-8","article-title":"GERD symptoms in the general population: prevalence and severity versus care-seeking patients","volume":"59","author":"Cohen","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.amjms.2016.12.013_bib37","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2010.04.009","article-title":"Involvement of mast cells in eosinophilic esophagitis","volume":"126","author":"Abonia","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.amjms.2016.12.013_bib39","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/blood.V126.23.5174.5174","article-title":"Utilities of various mast cell mediators in diagnosing mast cell activation syndrome","volume":"126","author":"Zenker","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib40","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/modpathol.2011.84","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume":"24","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.amjms.2016.12.013_bib41","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2016.12.013_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.amjms.2016.12.013_bib43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291630667X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000296291630667X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T01:03:16Z","timestamp":1601254996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000296291630667X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S000296291630667X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2016.12.013","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Mast Cell Activation Syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2016.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Southern Society for Clinical Investigation. Published by All rights reserved.","name":"copyright","label":"Copyright"}]}}